Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment
| Autor: | A. Kramar, P. Afchain, Rosine Guimbaud, M. Ychou, Thomas Aparicio, Emmanuelle Samalin, Françoise Desseigne, Antoine Adenis, Fadi Abbas, Emmanuel Mitry, Julien Edeline, Simon Thezenas, Yves Becouarn, Olivier Bouché, O. Romano, Etienne Dorval |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic medicine.medical_specialty Esophageal Neoplasms Adenocarcinoma Neutropenia Irinotecan Gastroenterology Folinic acid Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols FOLFIRI Regimen Humans Medicine Aged Retrospective Studies Aged 80 and over Hepatology business.industry Middle Aged medicine.disease Antineoplastic Agents Phytogenic Surgery Docetaxel Fluorouracil FOLFIRI Camptothecin Female Esophagogastric Junction business medicine.drug Epirubicin |
| Zdroj: | Clinics and Research in Hepatology and Gastroenterology. 35:48-54 |
| ISSN: | 2210-7401 |
| DOI: | 10.1016/j.gcb.2010.06.010 |
| Popis: | Summary Objectives The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status. We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts. Methods Two hundred and twelve pts from 13 French centers were treated with at least one cycle of FOLFIRI (irinotecan 180 mg/m 2 intravenous (i.v.) over 90 minutes on day 1 with folinic acid (FA) 400 mg/m 2 i.v. over two hours followed by 5-FU 400 mg/m 2 i.v. bolus then 5-FU 2400 mg/m 2 continuous infusion over 46 hours on day 1, repeated every 14 days). Primary tumour sites were 120 (58%) stomach and 92 (42%) gastroesophageal junction. FOLFIRI was administered as first-line in 137 (65%) pts and as later-line in 75 (35%) pts for MGA. Results There was no difference between chemonaive and not chemonaive pts treated as first-line in terms of response rate 37% (95% CI: 25–50) vs 44% (95% CI: 21–69), median PFS, 6.7 (95% CI: 5.5–9.9) vs 5.3 months (95% CI: 3.6–6.9) ( P = 0.25), and OS, 13.1 (95% CI: 11.7–18.7) vs 8.8 months (95% CI: 7.3–15.6) ( P = 0.19), respectively. There was no difference between pts treated as second or later-line in terms of response rate 20% (95% CI: 8–39) vs 22% (95% CI: 6–48), median PFS, four months (95% CI: 2.8–5.4) vs 3.5 months (95% CI: 2.3–4.5) ( P = 0.56), and OS, 10.4 months (95% CI: 5.4–14.4) vs 5.3 months (95% CI: 3.5–11.3) ( P = 0.58), respectively. The global grade 3–4 toxicities were: diarrhea 11%, vomiting 9%, neutropenia 18%, febril neutropenia 4% (one toxic death). Conclusions This retrospective study confirms the activity and good tolerance of FOLFIRI regimen in MGA as first-line as well as later-line. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|